Zhejiang Jolly Pharmaceutical: Sinolink's continuous supervision and follow-up report on Zhejiang Jolly Pharmaceutical Co., Ltd. for the first half of 2024.

SZSI · Jul 30

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.